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Developmental Fluoride 
Neurotoxicity: Clinical 
Importance versus Statistical 
Significance
http://dx.doi.org/10.1289/ehp.1206192
We were interested to read the article by 
Choi et al. (2012), who investigated the 
effects of increased fluoride exposure and 
delayed neuro behavioral develop ment by 
reviewing published studies and perform-
ing a meta-analysis. Of the 39 studies identi-
fied, the authors considered 27 to be eligible. 
Choi et al. reported a mean difference in IQ 
(intelli gence quotient) score between exposed 
and reference populations of –0.4 (95% con-
fidence interval: –0.5, –0.3) using a random-
effects model. Thus, children in high-fluoride 
areas had significantly lower IQ scores than 
those who lived in low-fluoride areas.
Even if we ignore the weaknesses of the 
study (Choi et al. 2012), including a lack of 
individual-level information and the high 
probability of confounding because the 
authors did not adjust for covariates, a dif-
ference of 0.4 in mean IQ is clinically neg-
ligible (Jeckel et al. 2007; Rothman et al. 
2008; Szklo and Nieto 2007) even though it 
was statistically significant. In general, clini-
cal importance takes priority over statistical 
significance. The p-value can easily change 
from significant to nonsignificant because of 
sample size or the mean difference and stan-
dard deviation of the variable in the study 
population (Jeckel et al. 2007; Rothman 
et al. 2008; Szklo and Nieto 2007). As Choi 
et al. (2012) pointed out in their conclusion, 
there is a “possibility of an adverse effect of 
high fluoride exposure on children’s neu-
rodevelopment.” Such a conclusion can be 
considered an ecological fallacy, which can 
easily lead to mis interpretation of the results. 
It is important to know that statistics can-
not provide a simple substitute for clinical 
judgment (Jeckel et al. 2007; Rothman et al. 
2008; Szklo and Nieto 2007).
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Sabour and Ghorbani’s comments about the 
reported mean difference in IQ (intelligence 
quotient) scores reported in our article (Choi 
et al. 2012) suggest a misunderstanding of the 
scale unit we used and the public health signifi-
cance of even a small decrease in the average 
IQ associated with exposure. We appreciate 
this opportunity to clarify the factual informa-
tion about the reported IQ measure.
The standardized weighted mean differ-
ence (SMD) in IQ score between exposed and 
reference populations was –0.45 (95% confi-
dence interval: –0.56, –0.35) using a random-
effects model (Choi et al. 2012). We used the 
SMD because the studies we included used 
different scales to measure the general intelli-
gence. The SMD is a weighted mean differ-
ence standardized across studies, giving the 
average difference in standard deviations for 
the measure of that outcome. For commonly 
used IQ scores with a mean of 100 and an SD 
of 15, 0.45 SDs is equivalent to 6.75 points 
(rounded to 7 points). As research on other 
neuro toxicants has shown, a shift to the left 
of IQ distributions in a population will have 
substantial impacts, especially among those in 
the high and low ranges of the IQ distribution 
(Bellinger 2007).
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Arsenic and Diabetes
http://dx.doi.org/10.1289/ehp.1206100
Maull et al. (2012) reviewed evidence link-
ing arsenic with diabetes in an evaluation 
that I believe could divert research resources 
from where they should properly be allo-
cated. I wish to make two points: 
•	The	review	gives	credibility	to	flawed	stud-
ies that conclude that the preva lence of 
diabetes is increased in people having urine 
arsenic concentrations in the upper 20% of 
the general U.S. population. 
•	The	authors	implied	that	we	need	studies	
assessing arsenic concentrations < 150 μg/L 
in drinking water, whereas research should 
actually focus on 150–500 μg/L. 
Regarding the first point, Table 2 of the 
review by Maull et al. (2012) reported an 
adjusted odds ratio (OR) of 3.58 for dia-
betes in the upper quintile of U.S. urinary 
arsenic concentrations (Navas-Acien et al. 
2008). When adjusted for sex, age, race, and 
creatinine (Navas-Acien et al. 2008), the OR 
was 0.82, and adjustment for four more fac-
tors resulted in an OR of 1.05. Navas-Acien 
et al. inserted two more variables into the 
regression model, including arseno betaine 
(a non toxic form of arsenic originating from 
fish), and the OR jumped up to 3.58. Never 
in the history of epidemiology have valid 
findings emerged from results like these. For 
> 20 years, arsenic researchers have been sub-
tracting arseno betaine from total arsenic in 
urine when assessing exposure to inorganic 
arsenic. When this is done, the OR estimate 
is 1.15 (Steinmaus et al. 2009a).
If the OR of 3.58 were valid, then very 
low concentrations of arsenic in water would 
be a major risk factor for diabetes. Among 
the 40 million or so adults within the highest 
quintile of urinary arsenic concentrations 
in the United States, > 4 million would 
become diabetic, attributable to low arsenic 
exposure. However, the OR estimate lacks 
scientific plausibility, with urine arsenic 
concentrations in the United States about 
10 times lower than those related to diabetes 
in Taiwan, Bangladesh, and elsewhere, and 
with U.S. water arsenic concentrations about 
50 times lower. 
In their Table 2, Maull et al. (2012) also 
cited another paper by the same authors 
that claims there are increased risks of dia-
betes related to arsenic in the United States 
(Navas-Acien et al. 2009). Again, the OR 
suddenly jumped up after inappropriately 
adding variables into the multi variate analy-
sis (Steinmaus et al. 2009b). Yet this review 
from Maull et al. (2012) presented Navas-
Acien et al.’s results as if they were from 
valid methods of analyzing the data. These 
analyses should not have been cited or their 
mistakes should have been acknowledged.
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